Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 AMPK signaling pathway 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
2 AMPK signaling pathway 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
3 Cytokine-cytokine receptor interaction 💬
1件: CSF2RA 💬 Molgramostim 💬 Molgramostim 2件: 229, 299 💬
4 Cytokine-cytokine receptor interaction 💬
1件: CSF2RA 💬 Regramostim 💬 Regramostim 1件: 229 💬
5 Cytokine-cytokine receptor interaction 💬
1件: CSF2RA 💬 Sargramostim 💬 Sargramostim 7件:  6 , 28, 60, 62, 96, 229, 285 💬
6 Efferocytosis 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
7 Efferocytosis 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
8 Hematopoietic cell lineage 💬
1件: CSF2RA 💬 Molgramostim 💬 Molgramostim 2件: 229, 299 💬
9 Hematopoietic cell lineage 💬
1件: CSF2RA 💬 Regramostim 💬 Regramostim 1件: 229 💬
10 Hematopoietic cell lineage 💬
1件: CSF2RA 💬 Sargramostim 💬 Sargramostim 7件:  6 , 28, 60, 62, 96, 229, 285 💬
11 Hematopoietic cell lineage 💬
1件: MS4A1 💬 Rituximab 💬 Rituximab 52件: 11, 13, 14, 19, 26, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 172, 220, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
12 Huntington disease 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
13 Huntington disease 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
14 JAK-STAT signaling pathway 💬
1件: CSF2RA 💬 Molgramostim 💬 Molgramostim 2件: 229, 299 💬
15 JAK-STAT signaling pathway 💬
1件: CSF2RA 💬 Regramostim 💬 Regramostim 1件: 229 💬
16 JAK-STAT signaling pathway 💬
1件: CSF2RA 💬 Sargramostim 💬 Sargramostim 7件:  6 , 28, 60, 62, 96, 229, 285 💬
17 Lipid and atherosclerosis 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
18 Lipid and atherosclerosis 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
19 Longevity regulating pathway 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
20 Longevity regulating pathway 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
21 Non-alcoholic fatty liver disease 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
22 Non-alcoholic fatty liver disease 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
23 Osteoclast differentiation 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
24 Osteoclast differentiation 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
25 Pathways in cancer 💬
1件: CSF2RA 💬 Molgramostim 💬 Molgramostim 2件: 229, 299 💬
26 Pathways in cancer 💬
1件: CSF2RA 💬 Regramostim 💬 Regramostim 1件: 229 💬
27 Pathways in cancer 💬
1件: CSF2RA 💬 Sargramostim 💬 Sargramostim 7件:  6 , 28, 60, 62, 96, 229, 285 💬
28 Pathways in cancer 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
29 Pathways in cancer 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
30 PPAR signaling pathway 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
31 PPAR signaling pathway 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
32 Thermogenesis 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
33 Thermogenesis 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
34 Thyroid cancer 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
35 Thyroid cancer 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
36 Transcriptional misregulation in cancer 💬
1件: NR1C3 💬 Pioglitazone hydrochloride 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬
37 Transcriptional misregulation in cancer 💬
1件: NR1C3 💬 Pioglitazone 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 81, 86, 96, 220, 229, 265, 298, 299 💬